Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 4/20 | 0.57 |
| ▸ | HRH3 | Q9Y5N1 | 9/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.55 |
| ▸ | HRH1 | P35367 | 1/20 | 0.55 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.52 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.50 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.49 |
| ▸ | LTA4H | P09960 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1870716 | 0.99 | HRH3 (0.57) | PTGS1HRH3KCNH2HRH1PTGS2 | |
| SCHEMBL1872837 | 0.91 | PTGS1 (0.54) | PTGS1HRH3KCNH2PTGS2PDPK1 | |
| SCHEMBL1884865 | 0.90 | HRH3 (0.56) | HRH3KCNH2HRH1HRH4LTA4H | |
| SCHEMBL1882421 | 0.84 | HRH3 (0.52) | PTGS1HRH3HRH1PTGS2 | |
| SCHEMBL1873980 | 0.84 | HRH3 (0.56) | PTGS1HRH3KCNH2HRH1PTGS2 | |
| SCHEMBL1878260 | 0.84 | HTT (0.57) | HRH3KCNH2HRH1HRH4LTA4H | |
| SCHEMBL1874165 | 0.84 | HRH3 (0.57) | PTGS1HRH3KCNH2 | |
| SCHEMBL1874163 | 0.84 | HRH3 (0.57) | PTGS1HRH3KCNH2 | |
| SCHEMBL1878122 | 0.83 | HRH3 (0.56) | PTGS1HRH3KCNH2HRH1PTGS2 | |
| SCHEMBL1881346 | 0.83 | PTGS2 (0.57) | HRH3KCNH2PTGS2LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1988777-B1 | PYRAZOLES FOR THE TREATMENT OF OBESITY AND OTHER CNS DISORDERS | ATHERSYS INC (US) | 2011-09-21 | — | — | EP | claimed |
| US-7897634-B2 | Pyrazoles for the treatment of obesity and other CNS disorders | ATHERSYS, INC. (US) | 2011-03-01 | — | — | US | claimed |
| US-20070197526-A1 | Pyrazoles for the treatment of obesity and other CNS disorders | ATHERSYS, INC. | 2007-08-23 | — | — | US | claimed |
| EP-1988777-B1 | PYRAZOLES FOR THE TREATMENT OF OBESITY AND OTHER CNS DISORDERS | ATHERSYS INC (US) | 2011-09-21 | — | — | EP | disclosed |
| US-7981896-B2 | Pyrazoles for the treatment of obesity and other CNS disorders | ATHERSYS, INC. (US) | 2011-07-19 | — | — | US | disclosed |
| US-20110112088-A1 | PYRAZOLES FOR THE TREATMENT OF OBESITY AND OTHER CNS DISORDERS | BENNANI YOUSSEF L | 2011-05-12 | — | — | US | disclosed |
| US-7897634-B2 | Pyrazoles for the treatment of obesity and other CNS disorders | ATHERSYS, INC. (US) | 2011-03-01 | — | — | US | disclosed |
| US-20070197526-A1 | Pyrazoles for the treatment of obesity and other CNS disorders | ATHERSYS, INC. | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112088-A1 | PYRAZOLES FOR THE TREATMENT OF OBESITY AND OTHER CNS DISORDERS | GPR119, HCRTR2, HCRTR1 | PTGS1 3045/4885HRH3 986/4885KCNH2 2244/4885 |
| US-20070197526-A1 | Pyrazoles for the treatment of obesity and other CNS disorders | HRH3, HRH4, HRH2 | PTGS1 2539/4885HRH3 1/4885KCNH2 1299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.